emtricitabine
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | EMTRIVA | — | 2006-12-22 – 2008-05-16 | fda.gov ↗ |
| Approved | EU (EMA) | Emtriva | — | 2003-10-24 | europa.eu ↗ |
| Approved | US (FDA) | EMTRIVA | — | 2003-07-02 | fda.gov ↗ |
Trials 268 · started per year
Also used as a comparator or background therapy in 191 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT04500847 Comparator | Dec 2021 → Mar 2026 overdue | cognitive impairment with or without cerebellar ataxia, early-onset autosomal dominant Alzheimer disease | Butler Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04760691 Comparator | Mar 2021 → Mar 2025 | HIV infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT04424264 Background | Dec 2019 → Oct 2020 | HIV infectious disease, tuberculosis | Professor Francois Venter | Completed | No outcome recorded |
| Phase 1 | NCT03719053 Background | Oct 2018 → Jun 2020 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT03186482 Comparator | Jun 2017 → Jan 2018 | HIV infectious disease | St. Stephens Clinical Research | Completed | No outcome recorded |
| Phase 1 | NCT02832778 Background | Nov 2016 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 1 | NCT02722343 Comparator | Apr → Aug 2016 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT02962739 Comparator | Mar 2016 → May 2019 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02499874 Background | Aug 2015 → Oct 2017 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT02203461 Background | Jul → Oct 2014 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT01694407 Comparator | Feb → Dec 2013 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01040091 Comparator | Dec 2009 → Apr 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00076791 Comparator | Mar 2004 → Mar 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07711223 Comparator | Nov 2025 → Aug 2028 expected | HIV infectious disease | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03251144 Background | Apr 2019 → Jul 2021 | AIDS, mitochondrial disease, poisoning | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT03577782 Background | Sep 2018 → May 2020 | HIV infectious disease | Hospitales Universitarios Virgen del Rocío | Unknown | No outcome recorded |
| Phase 1/2 | NCT03435146 Background | Jan 2018 → Dec 2022 | HIV infectious disease, respiratory tract infectious disorder | The Aurum Institute NPC | Completed | No outcome recorded |
| Phase 1/2 | NCT02475915 Background | Jan → Nov 2015 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT02022657 Comparator | Apr 2014 → Nov 2016 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT01632891 Background | Jan 2014 → Jun 2016 | HIV infectious disease, parasitemia | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 1/2 | NCT00364793 Background | Feb 2007 → Dec 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 235 trials | ||||||
| Phase 2 | NCT07288190 Background | May 2026 → May 2028 expected | HIV infectious disease, pregnancy disorder | HIV Prevention Trials Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07202546 Background | Feb 2026 → Jul 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 2 | NCT05719441 Background | Aug 2024 → Apr 2028 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT06631365 Background | Oct 2023 → Jan 2025 overdue | HIV infectious disease | Public Health Foundation Enterprises, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05729568 Background | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05458765 Comparator | Jun 2022 → Dec 2023 | — | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04824131 Background | Nov 2020 → Jan 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04692077 Background | Feb 2020 → Jul 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04097925 Background | Feb → Aug 2020 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 2 | NCT04012931 Background | Jul 2019 → Feb 2023 | HIV infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02415595 Background | May 2015 → May 2016 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02116660 Comparator | Sep 2014 → Jul 2017 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01687218 Comparator | Sep 2013 → May 2015 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 2 | NCT01803074 Background | Apr 2013 → Nov 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01632345 Background | Oct 2012 → Dec 2014 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01641809 Background | Aug 2012 → Oct 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01400412 Background | Jan 2012 → Jun 2014 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01403051 Background | Sep 2011 → Feb 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01291459 Background | Sep 2011 → Dec 2015 | HIV infectious disease | Association Pour la Recherche en Infectiologie | Unknown | No outcome recorded |
| Phase 2 | NCT01254656 Background | Feb 2011 → Apr 2013 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00799864 Background | Jan 2011 → Aug 2022 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT00959894 Background | Sep 2009 → Feb 2014 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00943540 Background | Jul 2009 → Dec 2010 | HIV infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00892437 Background | May → Dec 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00824421 Background | Feb 2009 → Oct 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00768989 Comparator | Nov 2008 → Jan 2010 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00752856 Comparator | Aug 2008 → May 2011 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT00654147 Comparator | Apr 2008 → Jan 2012 | HIV infectious disease | Margaret A. Fischl, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01174914 Comparator | Mar 2008 → Mar 2010 | — | The Ojai Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00551018 Comparator | Dec 2007 → May 2010 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00380159 Background | Sep 2006 → Dec 2008 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00110305 Background | Jun 2005 → Dec 2011 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00476463 Comparator | Apr 2005 → Dec 2008 | HIV infectious disease, hepatitis B virus infection | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT00120367 Background | Apr 2005 → Dec 2007 | HIV infectious disease, progressive multifocal leukoencephalopathy | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00006144 Background | Oct 2000 → Apr 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT06613685 Comparator | Oct 2024 → Mar 2026 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT06544733 Comparator | Aug 2024 → Jan 2028 expected | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04359095 Comparator | Aug 2020 → Mar 2021 | COVID-19 | National University of Colombia | Completed | No outcome recorded |
| Phase 2/3 | NCT02104700 Comparator | Apr 2014 → May 2016 | HIV infectious disease | Philip Grant | Completed | No outcome recorded |
| Phase 2/3 | NCT01154673 Background | Nov 2011 → Sep 2014 | — | University of Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT00448669 Comparator | Mar 2007 → Mar 2011 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/3 | NCT00391638 Background | Jan 2007 → May 2011 | HIV infectious disease, hepatitis B virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 356 trials | ||||||
| Phase 3 | NCT07683000 Background | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07075146 Comparator | May 2025 → Jun 2026 overdue | HIV infectious disease, obesity disorder | José Antonio Mata Marín | Recruiting | No outcome recorded |
| Phase 3 | NCT06203132 Comparator | Jan 2025 → Nov 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT06630299 Comparator | Oct 2024 → Apr 2026 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06273943 Comparator | Apr 2024 → Oct 2025 overdue | — | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05979311 Comparator | Feb 2024 → Apr 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06138600 Comparator | Nov 2023 → Oct 2025 | HIV infectious disease | University of Witwatersrand, South Africa | Unknown | No outcome recorded |
| Phase 3 | NCT05705349 Comparator | Mar 2023 → Oct 2025 overdue | HIV infectious disease | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04937881 Background | Jun 2022 → Apr 2023 | HIV infectious disease | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT04644029 Comparator | Feb 2021 → Jul 2023 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT04542070 Comparator | Nov 2020 → Jul 2022 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT04653194 Background | Sep 2020 → Jul 2023 | HIV infectious disease | Chelsea and Westminster NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT04223791 Comparator | Feb 2020 → Aug 2021 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT04079452 Background | Feb → Aug 2020 | HIV infectious disease | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT03227861 Background | Jul 2017 → Jan 2019 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02987530 Background | Apr 2017 → Jul 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT03122262 Comparator | Jan 2017 → Apr 2022 | HIV infectious disease | Professor Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02831673 Comparator | Jul 2016 → Mar 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02831764 Comparator | Jul 2016 → Apr 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02345226 Comparator | Jan 2015 → Jun 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02345252 Background | Jan 2015 → Jun 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02275780 Background | Dec 2014 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02302547 Background | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02131233 Background | May 2014 → Dec 2015 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01709084 Background | Oct 2013 → Oct 2015 | HIV infectious disease | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01435018 Background | Oct 2013 → Mar 2018 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT01910402 Comparator | Aug 2013 → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT01620944 Comparator | Jul 2012 → Jan 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT01605084 Background | Jun 2012 → Aug 2014 | HIV infectious disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT01473472 Comparator | Jan 2012 → Jun 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01516970 Background | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01475838 Comparator | Nov 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01363011 Background | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01309243 Background | Feb 2011 → Sep 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01237444 Comparator | Dec 2010 → May 2012 | HIV infectious disease | Pedro Cahn | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01066962 Comparator | Aug 2010 → Oct 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01108510 Background | Apr 2010 → Nov 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01033760 Background | Apr 2010 → Jul 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00928187 Comparator | Nov 2009 → Sep 2013 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00811954 Background | May 2009 → Jun 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00808002 Background | Feb 2009 → Nov 2011 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00454337 Background | May 2007 → Sep 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00089505 Background | Nov 2006 → Aug 2010 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00302822 Background | Apr 2006 → Dec 2009 | AIDS | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00262522 Comparator | Nov 2005 → Jul 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00272779 Comparator | Nov 2005 → Jun 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00105079 Background | Apr 2005 → Aug 2007 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01003990 Comparator | Oct 2002 → Feb 2016 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00043966 Background | Jul 2002 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 455 trials | ||||||
| Phase 4 | NCT07138144 Comparator | Jul 2025 → Feb 2026 overdue | HIV infectious disease | José Antonio Mata Marín | Recruiting | No outcome recorded |
| Phase 4 | NCT07031063 Comparator | Apr 2025 → Dec 2026 expected | HIV infectious disease, metabolic syndrome X | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06158126 Comparator | Apr 2024 → Dec 2026 expected | pregnancy disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT04636437 Comparator | Jul 2021 → Oct 2024 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT04884139 Comparator | Jul 2021 → Feb 2024 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT04880395 Comparator | May 2021 → May 2024 | HIV infectious disease | Fundación Huésped | Completed | No outcome recorded |
| Phase 4 | NCT04331704 Background | Jan 2021 → Dec 2025 overdue | alcohol-related disorders | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT04249037 Comparator | Dec 2020 → Jul 2023 | HIV infectious disease | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 4 | NCT04549467 Comparator | Nov 2020 → Sep 2023 | HIV infectious disease | Fundacion IDEAA | Completed | No outcome recorded |
| Phase 4 | NCT04442737 Comparator | Jul 2020 → Aug 2023 | — | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT04553081 Comparator | May 2020 → Jun 2026 overdue | HIV infectious disease | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT03986697 Comparator | Feb 2020 → Mar 2021 | HIV infectious disease, coronary atherosclerosis | University of Liverpool | Withdrawn | No outcome recorded |
| Phase 4 | NCT03387462 Background | Feb → Aug 2018 | — | Public Health Foundation Enterprises, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03126370 Background | Jan 2018 → Jul 2019 | coinfection, hepatitis C virus infection | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT02815566 Comparator | Sep 2017 → Feb 2021 | HIV infectious disease, osteoporosis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT03447873 Comparator | Jun 2017 → Sep 2020 | HIV infectious disease | Hospitales Universitarios Virgen del Rocío | Completed | No outcome recorded |
| Phase 4 | NCT03120494 Background | Nov 2016 → Jun 2019 | AIDS | Puerto Rico Community Network for Clinical Research on AIDS | Unknown | No outcome recorded |
| Phase 4 | NCT02322099 Comparator | May 2016 → Sep 2019 | disease of bone structure | University College Dublin | Terminated | No outcome recorded |
| Phase 4 | NCT02770508 Comparator | Nov 2015 → Jul 2017 | HIV infectious disease | Fundación Huésped | Completed | No outcome recorded |
| Phase 4 | NCT02529059 Background | Nov 2015 → May 2017 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 4 | NCT02547844 Background | Sep 2015 → Oct 2016 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02401230 Comparator | Mar 2015 → Jan 2017 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02285374 Background | Nov 2014 → Mar 2015 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 4 | NCT01902186 Comparator | Sep 2014 → Dec 2016 | HIV infectious disease | Giovanni Di Perri | Terminated | No outcome recorded |
| Phase 4 | NCT02159599 Comparator | Jul 2014 → Apr 2016 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT01829802 Comparator | May 2014 → Oct 2017 | HIV infectious disease | Pedro Cahn | Unknown | No outcome recorded |
| Phase 4 | NCT01147107 Background | Feb 2014 → Jun 2016 | HIV infectious disease, chronic hepatitis C virus infection | University of Hawaii | Completed | No outcome recorded |
| Phase 4 | NCT01869634 Comparator | Jun 2013 → Dec 2016 | HIV infectious disease | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT01781806 Comparator | May 2013 → May 2016 | — | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT01641367 Background | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01694017 Comparator | Nov 2012 → Aug 2014 | HIV infectious disease | Tufts University | Completed | No outcome recorded |
| Phase 4 | NCT01576731 Background | Jul 2012 → Jul 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01533272 Background | Feb 2012 → Jun 2014 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01471821 Background | Oct 2011 → Apr 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT01274780 Background | May 2011 → May 2013 | — | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT01335620 Background | Apr 2011 → Dec 2012 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT01338025 Comparator | Mar 2011 → May 2013 | HIV infectious disease | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Terminated | No outcome recorded |
| Phase 4 | NCT01258439 Comparator | Nov 2010 → Jul 2014 | HIV infectious disease, cardiovascular disorder | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
| Phase 4 | NCT01118871 Comparator | May 2010 → May 2013 | HIV infectious disease | Imperial College London | Terminated | No outcome recorded |
| Phase 4 | NCT01102972 Comparator | Apr 2010 → Jun 2012 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 4 | NCT00931801 Comparator | Dec 2009 → Feb 2012 | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Phase 4 | NCT00677300 Comparator | Jan 2009 → Oct 2012 | HIV infectious disease | Dallas VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00762892 Comparator | Jan 2009 → Dec 2012 | HIV infectious disease | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT00775606 Comparator | Oct 2008 → Dec 2010 | AIDS | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00757783 Background | Oct 2008 → Aug 2009 | HIV infectious disease | Tibotec, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00759070 Comparator | Sep 2008 → Jul 2013 | HIV infectious disease | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT00662545 Comparator | Apr 2008 → Feb 2010 | HIV infectious disease, hepatitis B virus infection | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00544128 Comparator | Oct 2007 → Feb 2012 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 4 | NCT00552240 Comparator | Sep 2007 → Mar 2010 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00532168 Background | Sep 2007 → Dec 2012 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00444379 Comparator | Apr 2007 → Feb 2012 | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00335322 Comparator | Feb 2007 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00192634 Comparator | Dec 2005 → Aug 2008 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00244712 Comparator | Jul 2005 → Apr 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07497594 Comparator | Feb 2026 → Feb 2029 expected | — | Oswaldo Cruz Foundation | Recruiting | No outcome recorded |
| — | NCT04712357 Comparator | Nov 2020 → Jan 2022 | COVID-19 | Federal University of Ceará | Unknown | No outcome recorded |
| — | NCT03988387 Background | Oct 2019 → Mar 2022 | HIV infectious disease | Columbia University | Completed | No outcome recorded |
| — | NCT03825523 Background | Jan 2018 → Aug 2025 | HIV infectious disease | Gustavo Reyes-Teran | Completed | No outcome recorded |
| — | NCT03012607 Background | Jan 2017 → Mar 2018 | HIV infectious disease | University of Washington | Completed | No outcome recorded |
| — | NCT03251690 Comparator | Oct 2016 → Apr 2018 | HIV infectious disease, hyperlipidemia | Mahidol University | Completed | No outcome recorded |
| — | NCT02827643 Comparator | Jun 2016 → Mar 2017 | bone disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT01929759 Background | Jan 2014 → Oct 2015 | HIV infectious disease | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01614405 Comparator | Jun 2012 → Jul 2015 | primary biliary cholangitis | University of Alberta | Terminated | No outcome recorded |
| — | NCT01293123 Background | Dec 2011 → Jun 2013 | HIV infectious disease | University of California, San Diego | Terminated | No outcome recorded |
| — | NCT01479634 Comparator | Oct 2011 → Jun 2015 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01450189 Comparator | Oct 2011 → Jul 2014 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00863668 Background | Mar 2009 → Mar 2010 | HIV infectious disease | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT00608569 Background | Mar 2009 → Sep 2012 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| — | NCT00641641 Background | Mar 2008 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| — | NCT00051831 Background | Oct 2003 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Press releases naming this drug 72 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-08-09 | Gilead Sciences | China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-26 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance gilead.com ↗ |
| 2018-12-04 | Gilead Sciences | China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-10-30 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-10-03 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-08-06 | Gilead Sciences | China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-07-24 | Gilead Sciences | Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States gilead.com ↗ |
| 2018-06-25 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-05-15 | Gilead Sciences | U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents gilead.com ↗ |
| 2018-04-27 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) gilead.com ↗ |
| 2018-03-05 | Gilead Sciences | Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗ |
| 2018-03-05 | Gilead Sciences | Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen gilead.com ↗ |
| 2018-02-07 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2017-10-04 | Gilead Sciences | Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗ |
| 2017-08-10 | Gilead Sciences | Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-07-24 | Gilead Sciences | Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-07-13 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ |
| 2017-06-12 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2017-05-30 | Gilead Sciences | Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies gilead.com ↗ |
| 2016-07-21 | Gilead Sciences | Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies gilead.com ↗ |
| 2016-06-23 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2016-04-29 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV gilead.com ↗ |
| 2016-04-25 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV gilead.com ↗ |
| 2016-04-04 | Gilead Sciences | U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy gilead.com ↗ |
| 2016-03-01 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2016-02-26 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2015-11-23 | Gilead Sciences | European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-11-05 | Gilead Sciences | U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2015-10-22 | Gilead Sciences | Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV gilead.com ↗ |
| 2015-09-25 | Gilead Sciences | European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV gilead.com ↗ |
| 2015-09-02 | Gilead Sciences | Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study gilead.com ↗ |
| 2015-08-20 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment gilead.com ↗ |
| 2015-07-21 | Gilead Sciences | Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) gilead.com ↗ |
| 2015-07-01 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) gilead.com ↗ |
| 2015-05-28 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2015-04-07 | Gilead Sciences | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment gilead.com ↗ |
| 2014-07-22 | Pfizer | ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗ |
| 2012-08-02 | Gilead Sciences | Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries gilead.com ↗ |
| 2011-11-15 | Gilead Sciences | Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista(R) with Emtriva(R), GS 7340 and Cobicistat gilead.com ↗ |
| 2008-08-01 | Gilead Sciences | Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries gilead.com ↗ |
| 2007-12-17 | Gilead Sciences | European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection gilead.com ↗ |
| 2007-12-11 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe gilead.com ↗ |
| 2007-10-18 | Gilead Sciences | European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) gilead.com ↗ |
| 2007-10-17 | Gilead Sciences | Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV gilead.com ↗ |
| 2006-12-15 | Gilead Sciences | 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗ |
| 2006-10-09 | Gilead Sciences | Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency gilead.com ↗ |
| 2006-09-28 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada gilead.com ↗ |
| 2006-08-14 | Gilead Sciences | 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗ |
| 2006-07-12 | Gilead Sciences | U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection gilead.com ↗ |
| 2006-04-27 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment gilead.com ↗ |
| 2006-01-18 | Gilead Sciences | Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗ |
| 2006-01-09 | Gilead Sciences | Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) gilead.com ↗ |
| 2005-08-09 | Gilead Sciences | Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva(R) (Efavirenz) gilead.com ↗ |
| 2005-07-22 | Gilead Sciences | Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest gilead.com ↗ |
| 2005-07-18 | Gilead Sciences | Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine gilead.com ↗ |
| 2005-04-26 | Gilead Sciences | Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada -emtricitabine and tenofovir disoproxil fumarate- and Sustiva -efavirenz- gilead.com ↗ |
| 2005-02-23 | Gilead Sciences | European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread gilead.com ↗ |
| 2005-02-03 | Gilead Sciences | Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ |
| 2004-10-31 | Gilead Sciences | Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ |
| 2004-08-26 | Gilead Sciences | Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ |
| 2004-08-02 | Gilead Sciences | U.S. FDA Approves Gilead's Truvada, a One-Tablet, Once-a-Day Fixed-Dose Co-Formulation of Viread and Emtriva as Part of HIV Combination Therapy gilead.com ↗ |
| 2004-07-11 | Gilead Sciences | Pivotal Studies of Gilead's Viread and Emtriva Published in Special International Aids Conference Issue of Journal of the American Medical Association gilead.com ↗ |
| 2004-03-15 | Gilead Sciences | Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva gilead.com ↗ |
| 2003-11-25 | Gilead Sciences | Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B gilead.com ↗ |
| 2003-10-28 | Gilead Sciences | Gilead Sciences' HIV Drug Emtriva Approved for Marketing in European Union gilead.com ↗ |
| 2003-08-11 | Gilead Sciences | Gilead Initiates Study 934, a 48-Week Clinical Trial Evaluating Viread and Emtriva versus Combivir gilead.com ↗ |
| 2003-07-24 | Gilead Sciences | European CPMP Gives Positive Opinion on Emtriva, Gilead's New Once-Daily Treatment for HIV gilead.com ↗ |
| 2003-07-14 | Gilead Sciences | Phase III Trial of Emtriva, New Once-Daily Capsule for HIV, Shows Continued Response Through 60 Weeks gilead.com ↗ |
| 2003-07-02 | Gilead Sciences | U.S. FDA Approves Gilead Sciences' Emtriva, a One-Capsule, Once-Daily Medication for the Treatment of HIV gilead.com ↗ |
| 2003-02-11 | Gilead Sciences | Phase III Data Show Emtricitabine Maintains Viral Load Suppression as Part of Once-Daily, Protease-Sparing Anti-HIV Regimen gilead.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 488 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emtricitabine | “The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing...” NCT06630286 ↗456“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗ “This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide...” NCT02707601 ↗ “This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗ “This single-arm, single-site, open-label trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part...” NCT02556333 ↗ “The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance...” PMID 33315694 ↗ Apr 2021 “The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among...” NCT02042001 ↗ “The study seeks to assess the safety of and define blood and tissue benchmark concentrations of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in...” NCT05140954 ↗ “This study aims: (1) to determine the optimal dose of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for daily oral pre-exposure prophylaxis (PrEP) during pregnancy...” NCT06435026 ↗ “Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease...” NCT02302547 ↗ “Individuals with HIV infection taking Efavirenz (EFV) and two nucleoside reverse transcriptase inhibitors (NRTI) who have undetectable (Groups 1 and 2) or detectable (Group 3...” NCT03435146 ↗ “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “To assess patient reported treatment satisfaction and medication tolerability in virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to a...” NCT05147740 ↗ “The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based...” PMID 30169223 ↗ Jun 2017 “Tenofovir / emtricitabine + efavirenz for all HIV-1-infected men and all HIV-1-infected women who meet the following requirements: on effective contraception and no history of...” NCT00495651 ↗ “The purpose of this study is to quantify the magnitude and extent of infant exposure to daily emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk...” NCT02776748 ↗ “Participants were prescribed coformulated (once-daily, oral tablet) tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) as HIV PrEP and were followed up with HIV...” PMID 34217426 ↗ Jul 2021 “Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine...” NCT06602622 ↗ “Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in...” NCT01796431 ↗ “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the...” NCT00110305 ↗ “A pod-IVR has been developed for the delivery of tenofovir (TFV) disoproxil fumarate (TDF) in combination with emtricitabine (FTC), as daily oral TDF-FTC is the only Food and...” PMID 30265679 ↗ Sep 2018 “The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing...” NCT02275780 ↗ “one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir...” NCT01614405 ↗ “Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate),...” NCT04644029 ↗ “Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg),...” NCT04965662 ↗ “Data support the use of single-tablet coformulated bictegravir (30 mg), emtricitabine (120 mg), and tenofovir alafenamide (15 mg) for treatment of HIV in children aged at least...” PMID 38621393 ↗ Apr 2024 “Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive patients infected by CCR5 HIV-1 previously treated for 6 months with a...” NCT01291459 ↗ “Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein...” PMID 20053692 ↗ Jan 2010 “Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet, will...” NCT07138144 ↗ “Relative Bioavailability Study to Investigate a Potential Interaction Between Dolutegravir (DTG) and Tenofovir Alafenamide Fumarate/Emtricitabine (F/TAF) Administered as...” NCT05489406 ↗ “Triple therapy consisted of lopinavir 400 mg and ritonavir 100 mg twice daily and lamivudine or emtricitabine plus another nucleoside reverse transcriptase inhibitor (NRTI) in...” PMID 24783988 ↗ Apr 2014 “Otherwise, patients can be initiated on a preferred regimen of tenofovir (TDF), emtricitabine (FTC), and efavirenz (EFV) according to the US Department of Health and Human...” NCT00799136 ↗ “The Effect of Rifampicin on the Plasma Pharmacokinetics of Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF) and Intracellular Tenofovir-diphosphate (TFV-DP) and...” NCT03186482 ↗ “Participants could choose between event-driven (2+1+1 dosing) and daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg), switch regimen, and...” PMID 34048794 ↗ May 2021 “Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for...” NCT03126370 ↗ “Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing...” NCT02322099 ↗ “Two drugs are combined in an FDA-approved pill called TRUVADA, containing the HIV medications, tenofovir disoproxil fumarate 300mg and emtricitabine 200mg, taken as one pill once a day.” NCT00594646 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States.” NCT04666792 ↗ “A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults” NCT02071082 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily” NCT01286740 ↗ “Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide [BIC/FTC/tenofovir alafenamide (TAF)] is effective for HIV treatment, it was evaluated for use for PEP.” PMID 34991141 ↗ May 2022 “B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements.” NCT06375304 ↗ “The investigators will investigate the effect of switching to Truvada (a combination pill of tenofovir and emtricitabine, the other two components of Atripla) plus raltegravir.” NCT01195467 ↗ “A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.” NCT00615745 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “Adults with HIV-1 RNA viral load of less than 50 copies/mL receiving daily bictegravir, emtricitabine, and tenofovir alafenamide combination (B/F/TAF) for 24 weeks or more.” PMID 41429026 ↗ Dec 2025 “A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period” NCT02652260 ↗ “Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg” NCT02591420 ↗ “Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz” NCT02827643 ↗ “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day” NCT01829802 ↗ “Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.” NCT03693508 ↗ “received either doravirine (100 mg) and islatravir (0·25 mg) or bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) orally once daily.” PMID 41763226 ↗ Feb 2026 “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya” NCT03052010 ↗ “Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily” NCT00525733 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal” NCT01309243 ↗ “SBRs include medicines like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+ tenofovir alafenamide (TAF)+ emtricitabine (FTC).” NCT07683000 ↗ “A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally” NCT04950530 ↗ “emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day” NCT00454337 ↗ “Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food” NCT01495702 ↗ “Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.” PMID 35815468 ↗ Aug 2022 “Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.” NCT00117676 ↗ “A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study” NCT00936715 ↗ “FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.” NCT01403051 ↗ “All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days” NCT01108926 ↗ “to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)” NCT03012607 ↗ “Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.” NCT04311957 ↗ “Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).” NCT01140880 ↗ “Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.” NCT03877536 ↗ “Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France” NCT03858478 ↗ “co-formulated Tenofovir Disoproxil Fumarate and Emtricitabine (FTC/TDF) plus combined ethinyl estradiol/levonorgestrel oral contraceptive (COC)” NCT07288190 ↗ “A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.” NCT04442737 ↗ “At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).” NCT00856323 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.” NCT00507689 ↗ “Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC)” NCT03227861 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “Drug-drug Interaction Study Between Bictegravir/Emtricitabine/Tenofovir Alafenamide and Feminizing Hormones in Trans Women Living With HIV” NCT05663892 ↗ “emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.” NCT04331704 ↗ “fixed tenofovir disoproxil fumarate (300 mg once daily) plus either lamivudine (300 mg once daily) or emtricitabine (200 mg once daily).” PMID 38788744 ↗ May 2024 “PrEP was prescribed as a fixed-dose combination of tenofovir disoproxil and emtricitabine (245 mg and 200 mg, respectively, per pill).” PMID 35772417 ↗ Jun 2022 “A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.” NCT04530630 ↗ “This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.” NCT04416906 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT00892437 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT01108510 ↗ “BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).” NCT04542070 ↗ “Truvada® (a fixed-dose combination tablet of emtricitabine \[FTC, 200 mg\] and tenofovir disoproxil fumarate \[TDF, 300 mg\])” NCT00324649 ↗ “Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information.” NCT00772902 ↗ “PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study.” NCT02043015 ↗ “Of 93 participants randomised to dolutegravir plus emtricitabine and 94 individuals to combination antiretroviral therapy” PMID 38754068 ↗ Apr 2024 “Generic TAF/E/D (tenofovir alafenamide 25mg/emtricitabine 200mg/dolutegravir 50 mg), a single-tablet once daily regimen” NCT03727152 ↗ “All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.” NCT02584140 ↗ “Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg” NCT04944654 ↗ “Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg” NCT04653194 ↗ “Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food” NCT05719441 ↗ “This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide” NCT05243602 ↗ “Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)” NCT02131233 ↗ “Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily” NCT01254656 ↗ “single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg)” PMID 28259776 ↗ Mar 2017 “Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.” NCT02401230 ↗ “600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily” NCT02556268 ↗ “Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily.” PMID 32265700 ↗ Mar 2020 “Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.” NCT02985996 ↗ “emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD” NCT00827112 ↗ “B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)” NCT03348163 ↗ “Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)” NCT04937881 ↗ “daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection” PMID 34379922 ↗ Aug 2021 “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗ “Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗ “once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy.” PMID 37939141 ↗ Nov 2023 “100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)” NCT05457530 ↗ “each in combination with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) (300/200 mg QD)” PMID 30352054 ↗ Oct 2018 “The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg).” NCT02722343 ↗ “Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine” NCT03986697 ↗ “using Tenofovir Disoproxil Fumarate plus Emtricitabine (FTC/TDF) in men and women at risk for HIV” NCT00971230 ↗ “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “the fixed-dose combination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 weeks” PMID 28219610 ↗ Feb 2017 “Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily” NCT01118871 ↗ “Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily” NCT00737568 ↗ “containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead)” NCT02593409 ↗ “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily” NCT03251144 ↗ “300 mg tenofovir disoproxil fumarate (TDF) in fixed dose combination with emtricitabine (FTC)” NCT03719053 ↗ “Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)” NCT04140266 ↗ “switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT00389194 ↗ “The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens” NCT00152061 ↗ “once-daily oral fixed-dose combination tenofovir alafenamide 25 mg and emtricitabine 200 mg” PMID 33010240 ↗ Oct 2020 “ETR 400 mg plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) 300/200 mg once daily” PMID 26263403 ↗ Aug 2015 “Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks” NCT01258439 ↗ “fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)” NCT03631732 ↗ “UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.” NCT00824421 ↗ “fixed-dose tablets of tenofovir alafenamide (10 mg or 25 mg) plus emtricitabine (200 mg)” PMID 29475804 ↗ Feb 2018 “coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate” PMID 24908550 ↗ Jun 2014 “lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor” PMID 26062880 ↗ Jun 2015 “oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis” PMID 33222803 ↗ Oct 2020 “Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily” NCT01147107 ↗ “Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate” NCT01690403 ↗ “tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year” NCT01694017 ↗ “switch or stay on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, n = 45)” PMID 39226296 ↗ Feb 2025 “bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; coformulated; Biktarvy®)” NCT06630299 ↗ “Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.” NCT03033836 ↗ “the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed” NCT00414635 ↗ “nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine” NCT03256422 ↗ “open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC)” PMID 31355775 ↗ 2019 “bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg)” PMID 38734016 ↗ May 2024 “didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated)” NCT00708162 ↗ “emtricitabine (FTC, F) and tenofovir alafenamide (F/TAF) versus emtricitabine” PMID 38312459 ↗ Jan 2024 “200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]” NCT04778514 ↗ “200mg emtricitabine and 300mg of tenofovir disoproxil fumarate (as Truvada®)” NCT02022657 ↗ “Combination of Tenofovir disoproxyl fumarate 300mg and Emtricitabine 200 mg” NCT02237027 ↗ “Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)” NCT00752856 ↗ “atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg” NCT01102972 ↗ “200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days” NCT04274595 ↗ “elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)” NCT02276612 ↗ “Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily” NCT04925752 ↗ “emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen” PMID 24908551 ↗ Jun 2014 “Name of Active Ingredients: Rilpivirine, tenofovir, emtricitabine” NCT02529059 ↗ “oral PrEP with emtricitabine plus tenofovir disoproxil fumarate” PMID 28986029 ↗ Oct 2017 “tenofovir disoproxil fumarate plus lamivudine or emtricitabine” NCT04183738 ↗ “tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg” PMID 41173578 ↗ Nov 2025 “bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]” NCT03825523 ↗ “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)” PMID 40982450 ↗ Sep 2025 “Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC)” NCT00039741 ↗ “Emtricitabine (FTC) 200 mg capsule taken orally once daily” NCT00507507 ↗ “emtricitabine 200 mg + tenofovir alafenamide 25 mg (F/TAF)” NCT05813964 ↗ “Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet” NCT04097925 ↗ “Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet” NCT04079452 ↗ “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04760691 ↗ “Emtricitabine/Tenofovir Disoproxil Fumarate; Truvada” NCT03593655 ↗ “tenofovir in addition to emtricitabine or lamivudine” NCT00662545 ↗ “Truvada is tenofovir 300 mg and emtricitabine 200 mg” NCT00762892 ↗ “Emtricitabine (FTC) Alone Versus HAART Interruption” NCT00362687 ↗ “Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF” NCT02246998 ↗ “Emtricitabine (FTC) 200mg po qd.(1-200mg capsule)” NCT00344461 ↗ “emtricitabine and tenofovir disoproxil fumarate” NCT02148094 ↗ “Bictegravir/emtricitabine/tenofovir alafenamide” NCT03797014 ↗ “Bictegravir/Emtricitabine/Tenofovir Alafenamide” NCT05630755 ↗ “Tenofovir 200mg/emtricitabine 300mg once a day” NCT01214759 ↗ “Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)” NCT06104306 ↗ “The NRTIs (including tenofovir/emtricitabine” NCT01516970 ↗ “Emtricitabine/Tenofovir Alafenamide (F/TAF)” NCT02016924 ↗ “Tenofovir Disoproxil Fumarate/Emtricitabine” NCT03834909 ↗ “Tenofovir disoproxil fumarate/emtricitabine” NCT03164564 ↗ “emtricitabine/tenofovir alafenamide (F/TAF)” NCT04994509 ↗ “Emtricitabine/Tenofovir Alafenamide (F/TAF)” NCT02285114 ↗ “ACC017+Emtricitabine/Tenofovir Alafenamide” NCT07711223 ↗ “Emtricitabine + tenofovir + efavirenz” NCT01174914 ↗ “emtricitabine/tenofovir alafenamide” PMID 37545387 ↗ Sep 2023 “emtricitabine 200 mg PO once daily” NCT01293123 ↗ “2. Emtricitabine 200 mg once a day” NCT02588820 ↗ “or emtricitabine (FTC - 200mg)” NCT06338826 ↗ “emtricitabine (FTC) 200 mg QD” NCT00262522 ↗ “emtricitabine 200 mg daily” NCT01367236 ↗ “TAF/emtricitabine (FTC)” NCT02771054 ↗ “Emtricitabine (200 mg)” NCT01605084 ↗ “emtricitabine \[FTC\]” NCT04012931 ↗ “emtricitabine (FTC)” NCT01338025 ↗ “emtricitabine (FTC)” PMID 30101539 ↗ Aug 2018 “emtricitabine (FTC)” NCT06337032 ↗ “emtricitabine,” NCT02157311 ↗ “Emtricitabine” NCT06631365 ↗ “emtricitabine” NCT01637259 ↗ |
| Known as | 524-W-91 | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | BW-524W91 | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Coviracil | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | emtricitabina | “Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.” NCT03577782 ↗ |
| Known as | emtricitabine (FTC) | “emtricitabine (FTC)” NCT01338025 ↗ |
| Known as | Emtricitabine component of atripla | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of biktarvy | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of complera | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of descovy | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of eviplera | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of genvoya | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of odefsey | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of stribild | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of symtuza | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabine component of truvada | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtricitabinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗ |
| Known as | Emtriva | “Emtriva (emtricitabine)” NCT00106379 ↗ |
| Known as | Emtriva (Brand for emtricitabine) | “Emtriva (Brand for emtricitabine)” NCT03304717 ↗ |
| Known as | FTC | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗171“This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗ “This single-arm, single-site, open-label trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part...” NCT02556333 ↗ “Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T),...” NCT02016924 ↗ “The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “This study aims: (1) to determine the optimal dose of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for daily oral pre-exposure prophylaxis (PrEP) during pregnancy...” NCT06435026 ↗ “In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) +...” PMID 38877762 ↗ Nov 2024 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir...” NCT02097381 ↗ “The purpose of this study is to quantify the magnitude and extent of infant exposure to daily emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk...” NCT02776748 ↗ “Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing...” NCT07006246 ↗ “The NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil...” PMID 30365452 ↗ Dec 2018 “A pod-IVR has been developed for the delivery of tenofovir (TFV) disoproxil fumarate (TDF) in combination with emtricitabine (FTC), as daily oral TDF-FTC is the only Food and...” PMID 30265679 ↗ Sep 2018 “The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC)...” PMID 22910324 ↗ Aug 2012 “In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons...” PMID 35943868 ↗ Sep 2022 “The investigators hypothesize that a drug interaction exists between DMPA and tenofovir/emtricitabine, such that levels of tenofovir (TFV) and emtricitabine (FTC) in...” NCT03197961 ↗ “Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)...” NCT00357552 ↗ “Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to...” NCT02831673 ↗ “Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 ↗ May 2014 “As of today, there is preclinical evidence, principally in vitro, indicating antiviral effect of Tenofovir Disoproxil Fumarate / Emtiricitabine (TDF/FTC) on the SARS-CoV-2 RNA...” NCT04519125 ↗ “The Effect of Rifampicin on the Plasma Pharmacokinetics of Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF) and Intracellular Tenofovir-diphosphate (TFV-DP) and...” NCT03186482 ↗ “Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national...” NCT07584122 ↗ “Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for...” NCT03126370 ↗ “Participants will receive either darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) fixed dose combination (D/C/F/TAF FDC) or DRV/COBI FDC...” NCT02431247 ↗ “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine/abacavir (DTG/3TC/ABC), are associated with metabolic, renal, and cardiovascular adverse effects” NCT07138144 ↗ “For this study, the following HIV treatment (or HAART) were provided in the form of a single tablet that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF).” NCT01403051 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States.” NCT04666792 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily” NCT01286740 ↗ “Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide [BIC/FTC/tenofovir alafenamide (TAF)] is effective for HIV treatment, it was evaluated for use for PEP.” PMID 34991141 ↗ May 2022 “First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study” NCT00660972 ↗ “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men who have sex with men (MSM).” PMID 26123937 ↗ Jun 2015 “Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.” NCT04583267 ↗ “Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.” NCT02269917 ↗ “A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period” NCT02652260 ↗ “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 2009 “BACKGROUND: It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect.” PMID 25870325 ↗ Apr 2015 “a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)” PMID 37752816 ↗ Sep 2023 “We evaluated a combination of fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) from the start (early combination) versus TDF as monotherapy.” PMID 20600025 ↗ Jun 2010 “Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF).” NCT00036452 ↗ “Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.” NCT03693508 ↗ “Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day” NCT05898841 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya” NCT03052010 ↗ “SBRs include medicines like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+ tenofovir alafenamide (TAF)+ emtricitabine (FTC).” NCT07683000 ↗ “Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.” NCT00117676 ↗ “Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).” NCT02530060 ↗ “Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women.” PMID 34041459 ↗ May 2021 “to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)” NCT03012607 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.” NCT00507689 ↗ “The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC).” NCT00955968 ↗ “emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “In this randomized study, we propose to evaluate long-term therapy with tenofovir alone or in combination with emtricitabine (FTC).” NCT00524173 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT01108510 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT00892437 ↗ “The fixed-dose combination of Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV or Atripla®) is a highly effective HAART combination” NCT00936195 ↗ “BIK was a fixed dose combination of 50 mg Bictegravir (BIC) + 200 mg Emtricitabine (FTC) + 25 mg Tenofovir alafenamide (TAF).” NCT04542070 ↗ “This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant chronic hepatitis B patients.” NCT02327702 ↗ “Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT02065986 ↗ “PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study.” NCT02043015 ↗ “This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV related cirrhosis patients.” NCT02327689 ↗ “providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with three adherence self-management interventions” PMID 36332953 ↗ Nov 2022 “Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012.” NCT04050371 ↗ “Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB) patients in China.” NCT02327676 ↗ “PrEP involves taking one pill daily of co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC).” NCT02870790 ↗ “Participants receive daily oral PrEP, composed of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)” PMID 27324719 ↗ Jun 2016 “Darunavir (DRV), emtricitabine (FTC), and tenofovir alafenamide (TAF) in the presence of cobicistat (COBI)” NCT04236453 ↗ “A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.” NCT02475135 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.” NCT03327155 ↗ “The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).” NCT02449733 ↗ “Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)” NCT04937881 ↗ “Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗ “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗ “100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)” NCT05457530 ↗ “once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy.” PMID 37939141 ↗ Nov 2023 “TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg)” NCT02150993 ↗ “using Tenofovir Disoproxil Fumarate plus Emtricitabine (FTC/TDF) in men and women at risk for HIV” NCT00971230 ↗ “with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC)” NCT04051970 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily” NCT00737568 ↗ “300 mg tenofovir disoproxil fumarate (TDF) in fixed dose combination with emtricitabine (FTC)” NCT03719053 ↗ “Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)” NCT04140266 ↗ “open label emtricitabine (FTC)/tenofovir (TDF) (Truvada®) as pre-exposure prophylaxis (PrEP)” NCT01769456 ↗ “switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT00389194 ↗ “The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens” NCT00152061 ↗ “DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC).” PMID 40874763 ↗ Feb 2026 “emtricitabine 1 tablet (FTC) / tenofovir (TDF) (200/300 mg) once a day orally for 12 months” NCT01989611 ↗ “emtricitabine 1 tablet (FTC) / tenofovir (TDF) (200/300 mg) once a day orally for 12 months” NCT03220152 ↗ “Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets” NCT07202546 ↗ “fixed-dose combination of emtricitabine (FTC) 200 mg + tenofovir alafenamide (TAF) 25mg” NCT05813964 ↗ “Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day” NCT03954327 ↗ “Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet” NCT04097925 ↗ “co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)” NCT01435018 ↗ “PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg” PMID 30084943 ↗ Jan 2019 “Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily” NCT00016718 ↗ “tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC)” NCT01910402 ↗ “combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs” PMID 31339677 ↗ Jul 2019 “oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC)” PMID 34878438 ↗ Jan 2022 “coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP” NCT01033942 ↗ “tenofovir disoproxil fumarate (TDF; 300 mg)-emtricitabine (FTC; 200 mg) tablets” PMID 18987623 ↗ Nov 2008 “open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC)” PMID 31355775 ↗ 2019 “didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated)” NCT00708162 ↗ “200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]” NCT04778514 ↗ “Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)” NCT04853524 ↗ “Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)” NCT07031063 ↗ “dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen” NCT05993767 ↗ “Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI)” NCT03304717 ↗ “generic emtricitabine(FTC) in Chinese naive chronic hepatitis B patients” NCT02327663 ↗ “common background of emtricitabine (FTC)/ tenofovir (TDF) 200/300 mg QD” NCT00757783 ↗ “Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)” NCT03251144 ↗ “open label emtricitabine (FTC)/tenofovir (TDF) (Truvada®) as PrEP.” NCT01772823 ↗ “daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]” NCT03988387 ↗ “daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)” PMID 28750059 ↗ Jul 2017 “either emtricitabine (FTC) (200 mg daily) or 3TC (300 mg daily)” PMID 41644158 ↗ Feb 2026 “bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]” NCT03825523 ↗ “Arm 1: Zidovudine (AZT), emtricitabine (FTC), efavirenz (EFV)” NCT00127959 ↗ “Tenofovir (TDF) with emtricitabine (FTC) and zidovudine (ZDV)” PMID 23639243 ↗ Apr 2013 “Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet” NCT04692077 ↗ “tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT02593409 ↗ “Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC)” NCT00039741 ↗ “tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg” NCT07349758 ↗ “Emtricitabine (FTC) 200 mg capsule taken orally once daily” NCT00507507 ↗ “Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04824131 ↗ “Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)” NCT02831764 ↗ “the NRTIs emtricitabine (FTC) and abacavir sulfate (ABC)” NCT00102206 ↗ “Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)” NCT00365612 ↗ “tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00335322 ↗ “Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)” NCT03255915 ↗ “Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00759070 ↗ “emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)” NCT00724711 ↗ “tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)” PMID 30212404 ↗ Sep 2018 “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04760691 ↗ “Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)” NCT03386578 ↗ “tenofovir (TDF) 300 mg/emtricitabine (FTC) 200 mg qd” PMID 22592092 ↗ May 2012 “FTC (emtricitabine) (solution or tablets) 6 mg/kg QD” NCT00364793 ↗ “Emtricitabine (FTC) Alone Versus HAART Interruption” NCT00362687 ↗ “tenofovir (TDF) 300mg + emtricitabine (FTC) 200mg” NCT00192634 ↗ “which are TDF (Tenofovir) and FTC (Emtricitabine)” NCT03251690 ↗ “Emtricitabine (FTC) 200mg po qd.(1-200mg capsule)” NCT00344461 ↗ “emtricitabine (FTC, F) and tenofovir alafenamide” PMID 38312459 ↗ Jan 2024 “Emtricitabine (FTC) Alone Vaginal Tablet” NCT01694407 ↗ “Tablet containing 200 mg FTC/300 mg TDF” NCT03593655 ↗ “EFV/emtricitabine (FTC)/truvada (TDF)” NCT01929759 ↗ “emtricitabine 200 mg (BIC/TAF/FTC)” NCT06602622 ↗ “Emtricitabine (FTC) 200 mg tablets” NCT02116660 ↗ “emtricitabine-tenofovir(FTC/TDF)” NCT02770508 ↗ “study drug, emtricitabine (FTC)” NCT00743340 ↗ “or emtricitabine (FTC - 200mg)” NCT06338826 ↗ “emtricitabine \[FTC, 200 mg\]” NCT00324649 ↗ “emtricitabine (FTC) 200 mg QD” NCT00262522 ↗ “tenofovir/emtricitabine (FTC)” PMID 23300238 ↗ Jan 2013 “emtricitabine (FTC; 200 mg)” NCT00112047 ↗ “Emtricitabine (FTC) 200mg” NCT01583439 ↗ “emtricitabine, FTC (drug)” NCT00196599 ↗ “emtricitabine, FTC (drug)” NCT00196612 ↗ “emtricitabine (FTC) 200mg” NCT01602822 ↗ “TAF/emtricitabine (FTC)” NCT02771054 ↗ “efavirenz (EFV)/FTC/TDF” PMID 30101539 ↗ Aug 2018 “emtricitabine \[FTC\]” NCT04012931 ↗ “Emtricitabine (FTC)” NCT07210528 ↗ “Emtricitabine (FTC)” NCT02984852 ↗ “Emtricitabine (FTC)” NCT01040091 ↗ “Emtricitabina (FTC)” NCT03577782 ↗ “emtricitabine (FTC)” NCT00799136 ↗ “emtricitabine (FTC)” NCT00006144 ↗ “emtricitabine (FTC)” NCT06337032 ↗ “emtricitabine (FTC)” NCT03631732 ↗ “Emtricitabine (FTC)” NCT00158457 ↗ |
| Action | Inhibit | “existing dual nucleoside analogue reverse transcriptase inhibitor therapy to coformulated tenofovir-emtricitabine or abacavir-lamivudine” PMID 24722774 ↗ Apr 2014 |
| Modality | Other / unclassified | “the NRTIs ddI and FTC” NCT00016718 ↗ |
| Route | Oral | “Will be administered as one 200-mg capsule orally daily” NCT00051831 ↗ |